NEW YORK (GenomeWeb News) – NextGen Sciences has spun off its “gene to protein’ automation and software business to a management-led buyout group called eXeTek Ltd.
Ann Arbor, Mich.-based NextGen said that the divestiture is in line with its previously announced plans to either sell or wind down the automation and software business and focus its resources on growing its protein biomarker services business. The firm’s biomarker discovery and assay development service, called biomarkerexpress, was launched in November 2007.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.